## AMENDMENTS TO THE CLAIMS

This listing of the claims replaces all prior versions, and listings, of claims in the application:

## **LISTING OF CLAIMS**

- 1. (Original) A method of treatment or prevention of damage due to radiation exposure comprising administering to a subject in need of such treatment an effective amount of a composition comprising 1) a compound including a radiation damage-inhibiting polypeptide comprising amino acid sequence LKKTET, a conservative variant of LKKTET, an actin-sequestering agent, an anti-inflammatory agent; 2) an agent which stimulates production of said compound in said subject; 3) an agent which regulates said compound in said subject; or 4) an antagonist of said compound, so as to inhibit radiation damage in said subject.
- 2. (Original) The method of claim 1 wherein said compound comprises a polypeptide comprising amino acid sequence LKKTET, or a conservative variant thereof.
- 3. (Currently Amended) The method of claim 1 wherein said polypeptide comprises amino acid sequence KLKKTET or LKKTETQ, Thymosin β4 (Tβ4), an N-terminal variant of Tβ4, a C-terminal variant of Tβ4, an isoform of Tβ4, a splice-variant of Tβ4, oxidized Tβ4, Tβ4 sulfoxide, lymphoid Tβ4, expegylated Tβ4, lymphoid Tβ4, expegylated Tβ4, lymphoid Tβ4, expegylated Tβ4, lymphoid Tβ4, lymphoid Tβ4, expegylated Tβ4, lymphoid Tβ4, lymp
- 4. (Original) The method of claim 1 wherein said compound is thymosin beta 4 (T $\beta$ 4).
- 5. (Previously Presented) The method of claim 1 wherein said compound is present in an injectable carrier, a gel, cream, paste, lotion, spray, salve, suspension, dispersion, hydrogel or ointment.

- 6. (Original) The method of claim 1 wherein said compound is delivered systemically to said subject by injection, infusion, pulmonary delivery, or orally, rectally, nasally, transdermally, or a combination thereof.
  - 7. (Original) The method of claim 1 wherein said agent is an antibody.
- 8. (Original) The method of claim 1 wherein said antagonist is an anti-sense form of said compound.
- 9. (Original) The method of claim 1 comprising administering said compound to said subject so as to protect radiosensitive stem cells in said subject.
- 10. (Original) The method of claim 1 wherein said stem cells are in blood, bone marrow or gastrointestinal tract tissue of said subject.
- 11. (Original) The method of claim 1 wherein said composition is administered systemically.
- 12. (Original) The method of claim 1 wherein said composition is administered topically.
- 13. (Original) The method of claim 1 wherein said composition is administered enterally.
  - 14. (Original) The method of claim 1 wherein said radiation is ionizing radiation.
- 15. (Original) The method of claim 1 further including a step of administering radiation to a target area of said subject so as to treat cancer or a tissue abnormality in said target area, wherein said composition is administered to said subject before, during or after administration of said radiation to said target area, or a combination thereof, so as to inhibit radiation damage in said subject outside said target area.
- 16. (Original) The method of claim 15 wherein said composition prevents induced apoptosis of cells of said subject outside said target area.

- 17. (Original) The method of claim 3 wherein said composition is contained in a formulation at a concentration within a range of about 0.001-10% by weight for administration to said subject.
- 18. (Withdrawn) A substance for use in manufacturing a medicament for treatment or prevention of damage due to ionizing radiation exposure, comprising 1) a compound including a radiation damage-inhibiting amino acid sequence LKKTET, a conservative variant of LKKTET, an actin-sequestering agent, an anti-inflammatory agent; 2) an agent which stimulates production of said compound in said subject; 3) an agent which regulates said compound in said subject; or 4) an antagonist of said compound, so as to inhibit radiation damage in said subject.